KalVista Pharmaceuticals (NASDAQ: KALV), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that it has closed on upsized underwritten public offering. The offering consisted of 6,181,250 shares of its common stock; an additional 806,250 shares were included in the offering, which were sold in accordance with the full exercise of the over-allotment option granted to underwriters. The shares were sold for $36 per share, with the offering ultimately resulting in an estimated $222.5 million in gross proceeds for KalVista. According to the announcement, Roth Capital Partners acted as co-manager for the offering.
To view the full press release, visit
https://ibn.fm/I3XhA
About KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (“HAE”) and diabetic macular edema (“DME”). KalVista is developing KVD900 (“KVD900”) as an oral on-demand therapy for acute HAE attacks, which completed a phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with an expected IND filing for a Phase 2 clinical trial in the first quarter of 2021. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001 (KVD001”), has completed a phase 2 clinical trial. For more information, please visit
www://ir.KalVista.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.